Medication keeps more patients with ANCA-associated vasculitis in remission than steroids
A Phase 3 clinical trial shows that Avacopan, which targets a receptor that attracts the cells that cause inflammation, was shown to be more effective at keeping patients in remission for a year than prednisone.
FULL STORY AT Penn Medicine News →